Email
Print
According to the latest market research report on the Biopharmaceuticals Manufacturing Consumables Testing Market, published by IndustryARC, The consistent growth in manufacturing capabilities of Biopharma is driving the demand for consumables and testing services crucial for ensuring product quality and regulatory compliance. As new production lines are added and existing ones are expanded, the Biopharmaceuticals Manufacturing Consumables Testing Market is poised for substantial growth. Companies in this sector must scale their offerings to meet the evolving needs of these expanding facilities, ensuring they provide innovative and reliable testing solutions that can keep pace with the industry's rapid advancements.
The Biopharmaceuticals Manufacturing Consumables Testing Market research report is segmented
By Service: Compendial & Multi-Compendial, Laboratory, Custom Testing / Customer Proprietary Testing
By Geography: North America, South America, Europe, APAC, Middle East & Africa which provides a comprehensive analysis of the global market & industry forecast (2025 - 2030).
Request Sample Research Report: https://www.industryarc.com/pdfdownload.php?id=508498
Asia Pacific Anticipated to Show the Fastest Growth in the Market:
Asia Pacific is projected to have the fastest growth rate in the biopharmaceuticals manufacturing consumables testing market, at 10.7% CAGR between 2025 and 2030. China and India are the key contributors to APAC's growth. The Chinese government's large expenditures on biotech and biopharmaceutical research have hastened the development of novel biologics, which is projected to drive up demand for consumables testing services. The Indian government has implemented advantageous policies such as the Draft R&D Policy 2021, PLI Schemes, and Clinical Trial Rules, propelling India to the status of 'pharmacy of the world'. These initiatives are encouraging investments in biopharmaceutical manufacture and, hence, the necessity for consumables testing.
Nations with substantial biopharmaceutical manufacturing capability investments include China, India, and South Korea. Region-specific governments are assisting by utilizing advantageous policies, monetary rewards, and infrastructure expenditures related to biotechnology. China’s "Made in China 2025" project is a prime example of this. Specialized manufacturing consumables and testing solutions are becoming more and more necessary as personalized medicine and gene therapies take hold. This is resulting in the development of niche biologics.
Biopharmaceuticals Manufacturing Consumables Testing Market 2024-2030: Scope of the Report
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Get Access to the Full Research Report: https://www.industryarc.com/Research/Biopharmaceuticals-Manufacturing-Consumables-Testing-Market-Research-508498
Biopharmaceuticals Manufacturing Consumables Testing Market Report – Key Takeaways:
- Compendial & Multi-Compendial are Leading the Market
Compendial & Multi-Compendial led the market with a 54.7% market share in 2024. The sustained dominance suggests that compliance with regulatory standards remains a critical priority for biopharmaceutical manufacturers, driving consistent demand for these testing services.
On January 20, 2022, the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response, is organizing a Biopharmaceutical Manufacturing Consortium (BioMaC) Industry Day. This consortium represents an intended expansion of the existing National Biopharmaceutical Manufacturing Partnership (BioMaP), which is managed by BARDA's Pharmaceuticals Countermeasure Infrastructure (PCI) division. The consortium aims to enhance the collaboration between the U.S. government and the industry in the manufacturing of medical countermeasures (MCM). It will bring together industry stakeholders from across the drug and vaccine manufacturing supply chain, including producers of essential raw materials, and consumables, and providers of fill-finish services. The BioMaC initiative is likely to drive significant growth and development in the Biopharmaceuticals Manufacturing Consumables Testing Market by emphasizing the importance of quality and safety in the manufacturing of critical medical countermeasures.
- North American Region Dominate The Market Share
The North American region in the Biopharmaceuticals Manufacturing Consumables Testing market is anticipated to hold a major share with a CAGR of 30.3% during the forecast period (2025-2030). The shift towards single-use systems in biopharmaceutical manufacturing is a primary driver in the North American biopharmaceutical manufacturing consumables testing market. This has led to an increased demand for testing services to validate the performance and safety of these materials under various bioprocessing conditions in the United States. Companies like Danaher and Thermo Fisher Scientific have invested heavily to meet the rising demand for single-use systems and other bioprocess consumables.
For example, Thermo Fisher invested $1 billion from 2020 to 2022 to expand its bioproduction capacity, focusing on cell culture, single-use technologies, and purification to alleviate substantial capacity limitations. Danaher has dramatically boosted its consumables spending, notably in the biopharma industry. In 2021, their capital investment in property, plant, and equipment nearly quadrupled in the first nine months, from $475 million to $874 million. Moreover, in August 2023, Danaher acquired Abcam, a prominent global provider of protein consumables to increase its position in the biopharmaceuticals market and improve its skills in mapping complicated illnesses and expediting drug discovery. This purchase emphasizes the importance of consumables in the biopharmaceutical industry and the necessity for rigorous testing to guarantee that these goods support advanced research and manufacturing.
- Increasing Use Of Single-Use Consumables Boosts The Market:
Nowadays, preclinical to commercial manufacturing stages of the drug development cycle are seeing an increase in the utilization of single-use (SU) technologies. For instance, maintaining sterility during powder and liquid transfers or open handling through manual filling is made simpler by using single-use bioprocess containers. As the biopharmaceutical business grows and dependence on single-use production grows, the demand for SU consumables such as bags, containers, filters, and tubing is also increasing.
Companies in the single-use consumables market are also making progress by introducing cutting-edge solutions such as single-use bioreactor systems to boost their profit. In September 2023, For instance, Getinge, a Swedish medical technology business, introduced the AppliFlex ST GMP. This single-use bioreactor is intended for clinical cell and gene treatments, providing scalability and a smooth transition from laboratory research to clinical manufacture of mRNA synthesis, gene therapy, and cell therapy. For bioprocessing applications, these bioreactor systems use disposable components such as plastic bags or containers rather than typical stainless steel or glass culture vessels.
Manufacturers must implement proper controls to manage risks associated with single-use technologies. GMP Annex 1 has a substantial influence on the utilization of single-use assemblies in fluid management operations within the biopharmaceutical sector. It requires manufacturers and stakeholders to take a risk-based approach, implement appropriate controls, and assure the integrity and sterility of single-use systems. This regulatory emphasis is boosting the demand for testing services to certify the quality and performance of single-use consumables, driving growth in the consumables testing market.
- Complexity And Cost Poses Challenge For The Market:
The complexity and cost of testing pose significant challenges for the Biopharmaceuticals Manufacturing Consumables Testing Market. As the biopharmaceutical industry continues to advance with more specialized and personalized therapies, the demand for consumables like filters, bags, and tubing has grown, leading to increasingly complex testing requirements. These consumables must meet stringent regulatory standards, including those set by the FDA and EMA, to ensure product safety and efficacy. However, the need for specialized testing methods, advanced technologies, and highly skilled personnel drives up operational costs, making it a barrier, especially for smaller manufacturers with limited resources. Additionally, the testing procedures for consumables often require extended timelines due to the complexity of the biopharmaceutical production process, further increasing costs. The high expense of compliance, coupled with the ongoing need to adapt to evolving industry standards, makes it difficult for manufacturers to balance quality assurance with cost-effectiveness, ultimately challenging the growth and scalability of the consumables testing market.
Purchase this Premium Report: https://www.industryarc.com/buynow?id=508498
Key Opportunity Analysis:
- 2023 VC Influx in Biopharma Sector Signals Growth in Consumables and Testing Services Demand
The 2023 Biopharma Industry Funding and Pipeline Report highlights a significant influx of venture capital (VC) into the biopharma sector, with Massachusetts-based companies alone securing $7.67 billion—31% of the total national VC investments, second only to California. Influencers in the investment community are viewing this as a strong indicator of the sector's growth potential, particularly in the areas of drug development and manufacturing. This funding surge is expected to drive increased demand for consumables and testing services as new companies and innovations enter the market.
With an expanding drug pipeline and a high number of FDA approvals reported for 2023, the biopharma sector is on a trajectory of rapid product development. Influencers in drug development and regulatory affairs are emphasizing the critical need for comprehensive testing solutions to support these new therapies. As companies accelerate their R&D efforts, the demand for consumables and testing services is projected to rise sharply, creating significant opportunities in the market.
- Surge in Biopharmaceutical R&D Investment Drives the Market
In the evolving landscape of medicine, where cutting-edge science is revolutionizing patient care and treatment approaches, biopharmaceutical companies are significantly increasing their research and development (R&D) investments. Over the past decade, member companies of PhRMA have more than doubled their yearly R&D expenditures, investing nearly $101 billion in 2022 to drive advancements and breakthroughs in developing new treatments and cures. As biopharmaceutical companies invest more in R&D, there will be a corresponding need for high-quality consumables and robust testing services to ensure the efficacy and safety of new products. This led to growth opportunities in the consumables testing market.
If you have any questions, please feel free to contact our experts at: https://connect.industryarc.com/lite/schedule-a-call-with-our-sales-expert
The Report also Covers the Following Areas:
- Biopharmaceuticals Manufacturing Consumables Testing Market Size and Forecast
- Biopharmaceuticals Manufacturing Consumables Testing Market Trends
- Biopharmaceuticals Manufacturing Consumables Testing Market Analysis by Type
Biopharmaceuticals Manufacturing Consumables Testing Market 2023-2030: Key Highlights
- CAGR of the market during the forecast period 2024-2030
- Value Chain analysis of key stakeholders
- Detailed analysis of market drivers and opportunities during the forecast period
- Biopharmaceuticals Manufacturing Consumables Testing Market size estimation and forecast
- Analysis and predictions on end users’ behavior and upcoming trends
- Competitive landscape and Vendor market analysis including offerings, developments, and financials
- Comprehensive analysis of challenges and constraints in the Biopharmaceuticals Manufacturing Consumables Testing Market
Covid and Ukrainian Crisis Impact:
- The COVID-19 pandemic has caused significant disruptions to global supply chains, impacting not just the transportation of completed items but also the cost and accessibility of raw materials. Both the COVID-19 pandemic and geopolitical crises disrupted global supply chains. Manufacturing facilities faced challenges in sourcing raw materials, production delays, and transportation issues, affecting the supply of Biopharmaceuticals Manufacturing Consumables Testing Technology.
- Price increases were caused by conflicts between Russia and Ukraine. Numerous businesses have temporarily closed their units in Ukraine and ceased operations in Russia. Additionally, because businesses are reluctant to engage in an area that is experiencing political and economic uncertainty, the Ukrainian crisis has also resulted in a decline in market investments. This can affect the market's dynamics of supply and demand.
To Get a Customized Industry Analysis, Speak with our Research Analyst: https://www.industryarc.com/reports/request-quote?id=508498
List of Top Companies in the Biopharmaceuticals Manufacturing Consumables Testing Technology Market:
The Global Biopharmaceuticals Manufacturing Consumables Testing Market is consolidated as the majority share is held by the leading Biopharmaceuticals Manufacturing Consumables Testing manufacturers. The key companies profiled are listed below:
- Eurofins Scientific
- Lonza
- SGS SA
- Agilent Technologies
- STERIS
- Catalent, Inc.
- Charles River
- Pace Analytical Services
- Alcami Corporation
Related Reports:
Biopharmaceutical Excipient Manufacturing Market – Throughout the forecast period, the biopharmaceutical excipient manufacturing market is anticipated to expand at a compound annual growth rate (CAGR) of 4.9%. The key factors driving this market include the rising prevalence of chronic diseases linked to sedentary lifestyles, significant investments by pharmaceutical companies in drug development, and the adoption of innovative technologies like nanotechnology.
Biopharmaceutical Market - The Biopharmaceutical Market is projected to grow at an estimated CAGR of 7.20 % by 2030. The ability of biopharmaceuticals to address life-threatening diseases is expected to fuel the growth of the biopharmaceuticals market. The approval of additional innovative biopharmaceutical products, along with ongoing research and development efforts, will further drive market expansion from 2024 to 2030.
Biopharmaceuticals Contract Manufacturing Market - The Biopharmaceuticals Contract Manufacturing Market is projected to grow at a CAGR of 9.4% by 2030. This growth is driven by rising research and development, supported by improved healthcare infrastructure and high healthcare spending in the region, which is boosting the market.
Biocatalysis & Biocatalysts Market - The Biocatalysis & Biocatalysts Market is projected to grow at an estimated CAGR of 7.5% by 2030. Growing awareness of the advantages of biocatalysts and their environmental sustainability across industries like food and beverages, detergents, starch processing, and textiles has driven an increase in demand. As a result, the market is projected to continue expanding during the forecast period.
About IndustryARC™:
IndustryARC primarily focuses on Market Research and Consulting Services specific to Cutting Edge Technologies and Newer Application segments of the market. The company’s Custom Research Services are designed to provide insights into the constant flux in the global demand-supply gap of markets.
IndustryARC’s goal is to provide the right information required by the stakeholder at the right point in time, in a format that assists an intelligent and informed decision-making process.
Contact Us:
Mr. Venkat Reddy
IndustryARC
Email: [email protected]
USA: (+1) 518-282-4727